课题基金 / 基金详情

项目摘要

项目成果

Praveen Mannam的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The aged have increased susceptibility to and mortality from acute lung injury and sepsis. Sepsis is a systemic inflammatory response to infection and is the leading cause of acute lung injury. The average age of people in the USA is projected to rise, and the disease burden in this population is likely to increase substantially. There is therefore a need to develop targeted biologic therapies to improve outcomes. Specific Aims: We propose to investigate MKK3, a mitogen-activated protein kinase signaling molecule, as a therapeutic target in sepsis-induced lung injury in the aged. For the first time, we identifie MKK3 as a critical mediator of acute lung injury in young mice challenged with endotoxin (LPS), an established mediator of sepsis. In the process, we found that MKK3 modulates key pathways associated with aging such as Nrf1, Sirt1, mitochondrial health and mitophagy. The role of MKK3 in aged mouse models of sepsis and in people is unknown. Our hypothesis is that MKK3 is an important determinant of acute lung injury and sepsis during aging. We propose to show that MKK3 activity increases with aging and correlates with worse outcomes in older septic mice and people with lung injury. We will: 1. Determine the role of MKK3 in age-related susceptibility to lung injury and mortality in a mouse model of sepsis. 2. Correlate MKK3 activity to age, severity of sepsis and susceptibility to lung injury in critically ill septic people. Experimental Approach: We will use a mouse model of endotoxic shock and also study the peripheral blood monocytes from critically ill septic patients. Objective: Our overall goal is to identify MKK3 as a important mediator of sepsis and lung injury in the aged. By using both animal models and clinical samples, we will show that MKK3 is a potentially effective therapeutic target in sepsis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MKK3 is a Mediator of Sepsis and Lung Injury in the Elderly
  • 批准号:
    8341044
  • 项目类别:
  • 资助金额:
    $8.3万
  • 财政年份:
    2012
  • 负责人:
    Praveen Mannam
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: